The aim of this study was to examine the quality of life and to report on the utility and QALY measures in patients before and after coronary artery bypass grafting (CABG); to investigate whether the SF-12 is comparable with the SF-36 for measuring health-related quality of life of patients with CABG; and to determine the impact of individual predictors on poor quality of life assessment after rehabilitation. This prospective study was conducted between January 2017 and December 2018 at the University Hospital Center Osijek, at three time points: pre-operation, 1 month after surgery, and after rehabilitation. The study was conducted with the SF-36 and SF-12 health questionnaires on 47 participants. After rehabilitation, there was a significant improvement in all domains of quality of life. The highest score was given to the change in pain (BP); mean scores were 63.8 (95% CI 56.9 to 70.6) (p = 0.001). The lowest grade (the lowest quality) after rehabilitation was in the domain of limitations due to physical difficulties (RP); arithmetic mean was 48.5 (95% CI 41 to 55.9) (p < 0.001). Quality-adjusted life-year was 0.41 (95% CI 0.38–0.44) after the CABG. The results of this study show that patients with coronary heart disease have poor quality of life before surgery. One month after the surgery, the quality of life improved, but was still inadequate. One year after surgery, satisfactory results were obtained in almost all subscales. The SF-36, SF-12, and its components, can be used effectively in patients with CABG. Age, gender, lifestyle, and risk factors in our sample of participants are not predictors of poor quality of life assessment after rehabilitation.

Background: The trends of recreational use of cannabis and the use of cannabis for medical indications (i.e., “medical cannabis”) have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making, and the strength of evidence for the medical use of cannabis is currently considered to be low. In contrast, there is growing evidence of negative health outcomes related to the use of cannabis. In this rapidly shifting landscape, the role of physician attitudes regarding the therapeutic value of cannabis has become essential. This study aimed to characterize knowledge/experience, attitudes, and potential predictors of clinical practice regarding medical cannabis.Methods: We conducted a cross-sectional survey of physicians from 17 countries between 2016 and 2018. The survey consisted of questions designed to explore physician knowledge, attitude, and practices regarding the use of medical cannabis. Descriptive statistics were used to examine willingness to recommend medical cannabis for medical and psychiatric indications, followed by regression analysis to identify the predictors of physician willingness to recommend medical cannabis.Results: A total of 323 physicians responded to the survey, among which 53% were women. The mean age was 35.4 ± 9.5 years, with 10.04 ± 8.6 years of clinical experience. Clinical experience with medical cannabis was overall limited (51.4% noted never having recommended medical cannabis and 33% noted inadequate knowledge regarding medical cannabis). The majority of respondents (84%) recognized the risk of psychosis with cannabis use, while only 23% correctly identified the risk of addiction with daily cannabis use. Overall, willingness to recommend medical cannabis was the highest for chemotherapy-induced nausea (67%), refractory chronic neuropathic pain (52%), and spasticity in amyotrophic lateral sclerosis (ALS; 51%).Conclusion: This international study examining physician knowledge, attitudes, and practices related to medical cannabis revealed that there are significant gaps in domain-specific knowledge related to medical cannabis. There is a wide variability in willingness to recommend medical cannabis, which is not consistent with the current strength of evidence. This study thus highlights the need for greater education related to domain-specific knowledge about medical cannabis.

Background The trends of recreational use of cannabis and use of cannabis for medical indications (i.e. “medical cannabis”) have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making and the strength of evidence for the medical use of cannabis is currently considered to be low. In contrast, there’s growing evidence for negative health outcomes related to use of cannabis. In this rapidly shifting landscape, the role of physician’s attitudes regarding the therapeutic value of cannabis has become essential. This study aimed to characterize knowledge/experience, attitudes, and potential predictors of clinical practice regarding medical cannabis. Methods We conducted a cross-sectional survey of physicians from 17 countries between 2016-2018. The survey comprised of 28 questions designed to explore physician knowledge, attitude, and practices regarding the use of medical cannabis. Descriptive statistics were used to examine willingness to recommend medical cannabis for medical and psychiatric indications, followed by regression analysis to identify predictors of physician willingness to recommend medical cannabis. Results A total of 323 physicians responded to the survey. Mean age was 35.4± 9.5 years, with 10.04 ±8.6 years of clinical experience. 53 percent of physicians were women. Clinical experience with medical cannabis was overall limited (51.4% noted never having recommended medical cannabis; 33% noted inadequate knowledge regarding medical cannabis). Overall willingness to recommend medical cannabis was highest for chemotherapy-induced nausea, refractory chronic neuropathic pain, and spasticity in amyotropic lateral sclerosis (ALS). Conclusion This international study examining knowledge, attitudes and practices related to medical cannabis among physicians revealed that there are significant gaps in domain-specific knowledge related to medical cannabis. There is wide variability in willingness to recommend medical cannabis that is not consistent with the current strength of evidence. This study thus highlights the need for greater education related to domain-specific knowledge about medical cannabis.

So far there is not much research considering female sex as a risk factor for developing focal cervical dystonia and concomitant psychiatric symptoms such as anxiety. New research proposes ideas of CD baseline pathophysiology targeting neurobiologica...

Introduction: The main goal of the research was to determine whether the doctors who work at the Clinical Medical Center Osijek are exposed to violence in the workplace, in what form of violence, whether there are differences in exposure between doctors according to age, gender and depending on whether they are specialists or residents. Participants and methods: This study is organized as a cross-sectional study. 101 doctors employed at the Clinical Medical Center Osijek participated in this research. The data were collected by answering an anonymous online questionnaire. Results: The majority of respondents who were exposed to violence at the workplace indicated that they had experienced verbal abuse (41.6%), followed by mobbing (21.8%), physical (5%) and sexual abuse (3%). Conclusion: Due to the small sample of the study, there are no significant differences in the distribution of respondents according to exposure to any form of violence in relation to gender, age or whether they are residents or specialists.

Measuring quality of life (QoL) in patients with early-stage lung cancer is an important aspect of treatment success. This study assessed QoL in the early postoperative period in patients with lung cancer, with regard to the type of cancer. This single-center study was conducted on 64 patients who underwent surgery for non-small cell (NSCLC) and small cell (SCLC) lung cancer. Quality of life questionnaires (QLQs) of the European Organization for Research and Treatment of Cancer (EORTC) were used. The EORTC QLQ-C30 questionnaire assesses the quality of life of cancer patients, and the EORTC QLQ-LC13 questionnaire is a lung cancer module. In the group of patients with NSCLC, the general health status (p < 0.001), physical functioning (p = 0.004), emotional functioning (p = 0.005) and total functional scale (p = 0.01) were significantly better assessed, fatigue was less pronounced (p = 0.005), nausea/vomiting (p = 0.04), pain (p = 0.004), breathing difficulties were less pronounced (p = 0.03), loss of appetite was less pronounced (p = 0.005), and the symptom scale was significantly less pronounced (p = 0.002) compared to patients with SCLC. In the QLQ-LC13 symptom scale, SCLC patients had more cough (p = 0.02), dyspnea (p = 0.03), dysphagia (p = 0.005), peripheral neuropathy (p = 0.04), chest pain (p < 0.001), arm or shoulder pain (p < 0.001), and pain in other parts of the body (p = 0.005) compared to NSCLC patients. Patients with NSCLC evaluated the functioning scales better and had less pronounced symptoms on the symptom scale, while patients with SCLC evaluated the treatment symptoms worse on the symptom scale, especially the symptom of pain, which had an impact on the quality of life of the patients. The results of this study could contribute to raising public awareness about the quality of life of lung cancer patients.